TY - JOUR
T1 - Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain
AU - Bandieri, Elena
AU - Romero, Marilena
AU - Ripamonti, Carla Ida
AU - Artioli, Fabrizio
AU - Sichetti, Daniela
AU - Fanizza, Caterina
AU - Santini, Daniele
AU - Cavanna, Luigi
AU - Melotti, Barbara
AU - Conte, Pier Franco
AU - Roila, Fausto
AU - Cascinu, Stefano
AU - Bruera, Eduardo
AU - Tognoni, Gianni
AU - Luppi, Mario
PY - 2016/2/10
Y1 - 2016/2/10
N2 - Purpose: The WHO guidelines on cancer pain management recommend a sequential three-step analgesic ladder. However, conclusive data are lacking as to whether moderate pain should be treated with either step II weak opioids or low-dose step III strong opioids. Patients and Methods: In a multicenter, 28-day, open-label randomized controlled study, adults with moderate cancer pain were assigned to receive either a weak opioid or low-dose morphine. The primary outcome was the number of responder patients, defined as patientswith a 20% reduction in pain intensity on the numerical rating scale. Results: A total of 240 patients with cancer (118 in the low-dose morphine and 122 in the weak-opioid group) were included in the study. The primary outcome occurred in 88.2% of the low-dose morphine and in 57.7% of the weak-opioid group (odds risk, 6.18; 95% CI, 3.12 to 12.24; P 30%) and highly meaningful (> 50%) pain reduction from baseline was significantly higher in the low-dose morphine group (P
AB - Purpose: The WHO guidelines on cancer pain management recommend a sequential three-step analgesic ladder. However, conclusive data are lacking as to whether moderate pain should be treated with either step II weak opioids or low-dose step III strong opioids. Patients and Methods: In a multicenter, 28-day, open-label randomized controlled study, adults with moderate cancer pain were assigned to receive either a weak opioid or low-dose morphine. The primary outcome was the number of responder patients, defined as patientswith a 20% reduction in pain intensity on the numerical rating scale. Results: A total of 240 patients with cancer (118 in the low-dose morphine and 122 in the weak-opioid group) were included in the study. The primary outcome occurred in 88.2% of the low-dose morphine and in 57.7% of the weak-opioid group (odds risk, 6.18; 95% CI, 3.12 to 12.24; P 30%) and highly meaningful (> 50%) pain reduction from baseline was significantly higher in the low-dose morphine group (P
UR - http://www.scopus.com/inward/record.url?scp=84958817595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958817595&partnerID=8YFLogxK
U2 - 10.1200/JCO.2015.61.0733
DO - 10.1200/JCO.2015.61.0733
M3 - Article
C2 - 26644526
AN - SCOPUS:84958817595
VL - 34
SP - 436
EP - 442
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 5
ER -